See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
• See links below
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  • Non-formulary
  • See MHRA Drug Safety Update
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
• See links below
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic).
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Approved for essential thrombocythaemia, if first-line hydroxycarbamide is unsuitable (JFC February 2020).

Provider notes

• NMUH:
• Approved for essential thrombocythaemia (see above)
• This drug for the treatment of malignant disease must be prescribed on chemocare 
• RFL:
• Approved for essential thrombocythaemia
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• See links below
• WH:
• No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • As per NICE TA492, TA520, TA525, TA584, TA638 & TA639
• RFL:
• As per NICE TA492, TA520, TA525, TA584/ CDF criteria
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• As per NICE TA520

See NICE TA for eligibility criteria 

Provider notes

• NMUH:
• Non-formulary
• RFL:
• As per NICE TA517/CDF criteria
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  
  • As per NICE TA333
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• Non-formulary
• This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines. 
• See link below
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Approved as first-line treatment for advanced squamous cell carcinoma of anus  (JFC March 2019). 

Note: Carboplatin AUC5 day 1 of 28 day cycles + paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of 28 day cycles. 6 cycles (each cycle 28 days) 

Provider notes

• NMUH:
• Non-formulary
• RFL:
• As above
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Approved as neo-adjuvant treatment before surgery for adenocarcinoma of the oesophagus or the gastro-oesophageal junction (JFC November 2017)

Provider notes

• NMUH:
• Non-formulary
• RFL:
• As above
• RNOH:
• Non-formulary
• UCLH:
  • As above
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • As per NICE TA
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • As per NICE TA 457

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• As per TA592
• RFL:
• As per TA592
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• Non-formulary
• WH:
• Non-formulary

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines. 
  • See link below
• RFL:
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • As per NICE TA

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• As per TA595
• RFL:
• As per TA595
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• Non-formulary
• WH:
• Non-formulary

Approved gastric or gastro-oesophageal junction adenocarcinoma (JFC November 2017)

Provider notes

• NMUH:
• Non-formulary
• RFL:
• As above
• RNOH:
• Non-formulary
• UCLH:
  • As above
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• Non-formulary
• This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
• As per NICE/CDF criteria
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• Non-formulary
• This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
• As per NICE TA
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• See links below
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

Approved for:

• 2nd / 3rd line treatment of inoperable gasto-oesophageal adenocarcinoma (May 2015)
• 2nd line for high grade neuroendocrine tumour (March 2016)

Provider notes

• NMUH:
• Non-formulary
• RFL:
• See above
• RNOH:
• Non-formulary
• UCLH:
• WH:

Approved for 1st line treatment of unresectable metastatic colorectal cancer (May 2015)

Provider notes

• NMUH:
• Non-formulary
• RFL:
• As above
• RNOH:
• Non-formulary
• UCLH:
• WH:

Approved adjuvant treatment of pancreatic cancer (JFC September 2018)

Provider notes

• NMUH:
• aS PER INDICATION ABOVE
• RFL:
• As above
• RNOH:
• Non-formulary
• UCLH:
• WH:
• As above

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotheray prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • See links below

Idelalisib should not be initiated as a first-line treatment in chronic lymphocytic leukaemia (CLL) patients with 17p deletion or TP53 mutation - see 'Direct Communication' below.

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • See link below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• Non-formulary
• RFL:
• As per NICE guidance for renal cell carcinoma
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

DO NOT CONFUSE Kisplyx^® AND Lenvima^® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
  • TA551 does not apply at NMUH as service is not offered
• RFL:
• As per NICE guidance for thyroid cancer and hepatocellular carcinoma
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• Non-formulary
• This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
• As per NICE guidance
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• As per NICE TA612
• RFL:
• As per NICE TA612
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• As per NICE TA612

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• See links below
• TA400, TA417, TA530, TA558 and TA581 do not apply at NMUH as service is not offered
• RFL:
• As per NICE TA
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• See links below

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • Non-formulary (TA381, TA598 and TA620 does not apply at NMUH as service is not offered) 
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
  
  • Approved for
    
    • Fallopian tube cancer (in line with NICE TA 381 and 620) 
    • Primary peritoneal cancer (in line with NICE TA 381 and 620) 
    • Relapsed platinum-sensitive BRCA mutated high grade serous ovarian cancer (in line with NICE TA 381 and 620)
• WH:
  
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  • As per NICE TA495, TA619
• RFL:
  
  • As per NICE TA495
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
  • Check for MHRA Drug Safety Updates
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• To be prescribed Oncology Consultants ONLY.
• See links below
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • For Paediatric patients, the supply is made from GOSH
  • See links below
• RFL:
  • Formulary for paediatrics
  • For Paediatric patients, the supply is made from GOSH
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• As per NICE TA428, TA447, TA519, TA522, TA531, TA540, TA557, TA600
• TA357, TA366 and TA553 do not apply at NMUH as service is not offered
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• See links below

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • See link below

Provider notes

• NMUH
  • As per TA496, TA593 
• RFL
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH
  
  • Non-formulary
• UCLH
• WH

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See link below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • See link below

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  
  • As per NICE TA
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• RFL:
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  •  This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)

• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • Discuss with cancer pharmacy team before prescribing
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• To be prescribed by the Haematology Team ONLY
• See links below
• RFL:
• As per NICE guidance/CDF criteria
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • As per NICE TA478, TA524, TA641
  • TA577 does not apply at NMUH as service is not offered
• RFL:
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL elecctronic chemotherapy prescribing system)
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • As per NICE TA478, TA524, TA577. 

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• Check MHRA Drug Safety Updates
• See links below
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • Non-formulary
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• Positive NICE TA This medicine has a positive NICE Technology Appraisal but the service is not provided at NMUH.
• Check MHRA Drug Safety Updates
• RFL:
• Restricted to neuroendocrine (NET) patients (with capecitabine) and metastatic melanoma
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary to WH

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when use in line with NICE recommendations and/or Local Trust Guidelines.
  • To be prescribed by the Oncology team ONLY.
  • As per NICE guidance TA258, TA374.

• RFL:
  
  • As per NICE guidance TA258, TA374.
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Gilvec for GIST only.

Generic for all other indications.

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • To be prescribed by the Haematology Team ONLY.
  • See links below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • As per NICE TA

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  
  • As per NICE TA
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Approved for metastatic adrenocortical carcinoma (JFC February 2018)

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• See links below
• RFL:
• Restricted for treatment of pancreatic, colorectal, oesophago-gastric cancers and lymphoma only
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See link below
• RFL:
  
  • As per NICE TA
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • Non-formulary
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  
  • As per NICE guidance for the treatment of medullary thyroid cancer
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  
  • As per NICE guidance for the treatment of renal cell carcinoma
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary to WH

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
  • Check MHRA drug safety alerts
  • See London Cancer Guidelines for the Treatment of Lung Cancer
• RFL:
  
  • As per NICE TA
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additonally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
  • In line with NICE TA's
  • In line with Cancer Drug Fund
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patient this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• As per NICE TA643
• RFL:
• Non-formulary
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
• TA432, 449 and 498 do not apply at NMUH as services not offered.
• See links below
• RFL:
• As per NICE guidance (see below)
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

DO NOT CONFUSE Afinitor^®, Votubia^® AND Certican^® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS.

Approved for:

• renal angiomyoplipomas who are at risk of complications but who do not require immediate surgery, and is reserved for patients with multiple AMLs in one or both kidneys and one or more lesions of >3cm in diameter. Restricted to renal consultants in renal genetics specialist clinic only (JFC July 2013)
• refractory focal onset seizures associated with tuberous sclerosis complex (TSC) in line with NHS England Commissioning Policy (JFC June 2019)

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Approved for renal angiomyoplipomas (see above and NHSE Commissioning Policy)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • To be prescribed by the Oncology Team ONLY.
  • See links below
• RFL:
  
  • Approved for non-small cell lung cancer in line with NICE
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Restricted to the treatment of NSCLC with EGFR mutation.

Provider notes

• NMUH:
  
  • Special Funding Approval required - seek advice from Oncology Pharmacist
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • As per TA628
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • To be prescribed Oncology Consultants ONLY.
  • See links below
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• As per NICE TA416
• RFL:
• As per NICE TA416
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  
  • Approved for metastatic renal cell carcinoma only in line with NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary to WH

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
  
  • Non-formulary
• UCLH:
  • No restriction stated
• WH:
  
  • Non-formulary to WH

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
  • TA178 and TA474 do not apply at NMUH as service is not offered/drug not recommended.
• RFL:
  
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic) 
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary to WH

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• Check MHRA drug safety updates
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  
  • As per NICE TA
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary to WH

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• RFL:
• No restrictions stated
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Breast and lung cancer

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below 
• RFL:
  • No restrictions stated
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

See NICE TA for eligibility criteria

Approved for:

• Adjuvant or neoadjuvant therapy and metastatic disease breast cancer for those with hypersensitivity to taxanes. Hypersensitivity is defined as grade 3 hypersensitivity (JFC August 2013).
• See NICE TA476 for use of Abraxane for other cancers

Provider notes

• NMUH:
• As per NICE TA476 and TA639.
• RFL:
• Restricted to breast and pancreatic cancer patients as per NHS England criteria and NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• As per NICE TA476

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• To be prescribed by the Oncology team only.
• See links below
• RFL:
• No restriction stated
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

See NICE TA for eligibility criteria

Providernotes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• TA183 not applicable at NMUH as service is not offered.
• See links below
• RFL:
• As per NICE guidance
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Topotecan is available for the treatment of relapsed SCLC

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
  • See Link below
• RFL:
  • As per NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
• RFL:
• Non-formulary
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• See links below
• RFL:
• As per NICE guidane
• This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• See links below

IV or SC

See NICE TA for eligibility criteria

Use Ontruzant brand as first choice IV trastuzumab (JFC July 2018).

Provider notes

• NMUH:
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  
  • Approved for breast cancer and adenocarcinoma of the stomach in line with NICE guidance
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • See links below
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Trastuzumab is indicated for metastatic breast cancer as per Cancer Network Guidelines

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • As per NICE TA458, TA632
• RFL:
  
  • As per NICE TA458
  • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • As per NICE TA458

Provider notes

• NMUH:
  • To be prescribed by the Haematology Team ONLY in emergencies prior to the patient being transferred to UCLH. This is kept in the Emergency Drug Cupboard ONLY. This is a critical medicine and doses must not be delayed.
• RFL:
  • To be prescribed by the Haematology Team ONLY in emergencies prior to the patient being transferred to UCLH. This is kept in the Emergency Drug Cupboard ONLY. This is a critical medicine and doses must not be delayed.
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  
  • To be prescribed by the Oncology Team ONLY if CDF funded
• RFL:
  
  • Non-formulary

• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary